The Cancer Prevention Program ofthe Robert H. Lurie Comprehensive Cancer Center is a multi-disciplinary program focusing on three thematic areas: novel strategies for cancer risk stratification and early detection, innovative behavioral interventions to reduce cancer risk, and the discovery and development of new devices and therapeutics to reduce cancer risk. The Program Leader is Raymond Bergan, MD, an eminent molecular pharmacologist whose research focuses on cancer chemopreventive agents, and the Program Co-Leader is Bonnie Spring, PhD, a distinguished psychologist who studies behavioral risk factors. The objective ofthe Cancer Prevention Program, comprised of 28 faculty members from 11 departments and 3 schools, is to facilitate and focus research on primary and secondary cancer prevention within the Cancer Center. Between August 2007 and July 2012 there were 401 cancer-relevant publications from the Cancer Prevention Program members. Fifty-three (13.2%) of these publications represent intra-programmatic collaborations and 175 (43.6%) of these publications represent inter-programmatic collaborations. Further, a total of 6,247 individuals were entered on to Cancer Prevention Program studies, with 1,111 entered on to interventional trials. Total cancer relevant funding for the Prevention Program is $12,328,943, with 85% coming from peer reviewed funding. Peer reviewed funding is $10,466,682 (total) and $7,633,648 (direct), with $3,134,489 (41%) from NCI and $4,499,160 (59%) from national level peer reviewed sources. The goals ofthe Program are: i. to identify new methods of risk stratification and early detection, ii. to develop innovative strategies to reduce cancer risk behaviors, and iii. to discover and develop novel therapeutic approaches to reduce cancer risk. The contribution of prevention efforts to recent declines in cancer mortality, the demonstrated success of cancer chemopreventive agents, and evidence indicating that the large majority of cancers are caused by environmental factors (many of which are linked to behavior), coupled with the inherent humanitarian and economic logic of preventing cancer, all support the importance of this work. This Program actively seeks to expand the capabilities and efficacy of cancer prevention by developing and employing cutting edge technology, measurement tools and methods, and drug- and behavior-based interventional strategies. It does so by leveraging members'interests and capabilities across disciplines. The Program's integrated focus on cancer prevention provides an environment that fosters intra and inter-program collaboration, and has spawned cutting-edge advances in the field.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northwestern University at Chicago
United States
Zip Code
Caralt, M; Uzarski, J S; Iacob, S et al. (2015) Optimization and critical evaluation of decellularization strategies to develop renal extracellular matrix scaffolds as biological templates for organ engineering and transplantation. Am J Transplant 15:64-75
Hung, Andy H; Holbrook, Robert J; Rotz, Matthew W et al. (2014) Graphene oxide enhances cellular delivery of hydrophilic small molecules by co-incubation. ACS Nano 8:10168-77
Gach, Johannes S; Achenbach, Chad J; Chromikova, Veronika et al. (2014) HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One 9:e85371
Zhao, Baobing; Keerthivasan, Ganesan; Mei, Yang et al. (2014) Targeted shRNA screening identified critical roles of pleckstrin-2 in erythropoiesis. Haematologica 99:1157-67
Keller, Jacob Pearson; Homma, Kazuaki; Duan, Chongwen et al. (2014) Functional regulation of the SLC26-family protein prestin by calcium/calmodulin. J Neurosci 34:1325-32
Daugherty, Rebecca L; Serebryannyy, Leonid; Yemelyanov, Alex et al. (2014) ?-Catenin is an inhibitor of transcription. Proc Natl Acad Sci U S A 111:5260-5
Jensen, Samuel A; Calvert, Andrea E; Volpert, Giora et al. (2014) Bcl2L13 is a ceramide synthase inhibitor in glioblastoma. Proc Natl Acad Sci U S A 111:5682-7
Cull, Elizabeth H; Altman, Jessica K (2014) Contemporary treatment of APL. Curr Hematol Malig Rep 9:193-201
Anderson, Mark T; Dewenter, Lena; Maier, Berenike et al. (2014) Seminal plasma initiates a Neisseria gonorrhoeae transmission state. MBio 5:e01004-13
Gopal, Satish; Achenbach, Chad J; Yanik, Elizabeth L et al. (2014) Moving forward in HIV-associated cancer. J Clin Oncol 32:876-80

Showing the most recent 10 out of 316 publications